Earnings · China A-shares
Gan & Lee Pharmaceuticals Co., Ltd. Class A (603087) earnings
Gan & Lee Pharmaceuticals Co., Ltd. Class A published its Q3 report on 2026-10-27: net profit +4.86% year on year, +17.96% excluding one-off items. Wave Radar's earnings-quality score is 100 of 100 (Sound). The stock moved -0.01% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-27
- Period end
- 2026-09-30
- Net profit YoY
- +4.86%
- Excl. one-offs YoY
- +17.96%
- Net profit QoQ
- -40.50%
- Result
- Neutral
- Quality score
- 100
- Quality
- Sound
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | -0.37% | — |
| 3 days | -0.01% | — |
| 7 days | +5.87% | — |
| 14 days | -6.16% | — |
Report history
Over the last 8 reports, net profit grew year on year in 7 of them. The stock rose in the 3 trading days after 2 of 6 reports (average -1.59%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-28 | ¥858.09M | +4.86% | +17.96% | +10.57% | 1.45 | 7.25% | -0.01% | — | — |
| 2026 interim report | 2026-08-26 | ¥609.78M | +1.01% | +18.91% | +7.56% | 1.03 | 5.15% | +2.33% | +0.01% | +7.01% |
| 2026 Q1 report | 2026-04-23 | ¥192.49M | -38.29% | -13.31% | -10.84% | 0.33 | 1.64% | -8.69% | -14.75% | -13.20% |
| 2025 annual report | 2026-04-23 | ¥1.14B | +86.05% | +81.21% | +33.06% | 1.93 | 10.08% | -8.69% | -14.75% | -13.20% |
| 2025 Q3 report | 2025-10-31 | ¥818.34M | +61.32% | +122.83% | +35.73% | 1.38 | 7.21% | -7.90% | -6.62% | -1.94% |
| 2025 interim report | 2025-08-08 | ¥603.68M | +101.96% | +284.47% | +57.18% | 1.02 | 5.32% | -2.32% | +16.41% | +7.03% |
| 2025 Q1 report | 2025-04-25 | ¥311.92M | +224.90% | +1150.17% | +75.76% | 0.53 | 2.78% | +7.07% | +28.53% | +25.29% |
| 2024 annual report | 2025-04-25 | ¥614.66M | +80.75% | +44.85% | +16.77% | 1.04 | 5.55% | +7.07% | +28.53% | +25.29% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.